Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors
Isis Torréns(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Cirse Mesa(Center of Molecular Immunology (Cuba)), Aileen Batte(Centro de Ingeniería Genética y Biotecnología), Luis E. Fernández(Center of Molecular Immunology (Cuba)), Osvaldo Reyes, Osmani Mendoza(Centro de Ingeniería Genética y Biotecnología)
Cited by 33
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134